The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Incyte; MSD Oncology; Novartis Italy; Pierre Fabre; Sanofi
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pierre Fabre
First-in-human (FIH) phase I study of the highly selective phosphoinositide 3-kinase inhibitor delta (PI3Kδ) inhibitor IOA-244 in patients with advanced cancer: Safety, activity, pharmacokinetic (PK), and pharmacodynamic (PD) results.
 
Anna Maria Di Giacomo
No Relationships to Disclose
 
Federica Santangelo
No Relationships to Disclose
 
Giovanni Amato
No Relationships to Disclose
 
Elena Simonetti
No Relationships to Disclose
 
Jill Graham
No Relationships to Disclose
 
Michael M. F. Lahn
Employment - iOnctura
Leadership - iOnctura
Stock and Other Ownership Interests - Incyte; iOnctura
Consulting or Advisory Role - Nouscom; Step Pharma
 
Lars Anders van der Veen
Employment - iOnctura
Leadership - iOnctura
Stock and Other Ownership Interests - iOnctura
 
Zoe Johnson
Employment - iOnctura
Leadership - iOnctura
Stock and Other Ownership Interests - iOnctura
Research Funding - iOnctura
Patents, Royalties, Other Intellectual Property - I am a named inventor on several patents wholly owned by my employer, iOnctura, as declared in my COI
Travel, Accommodations, Expenses - iOnctura
 
Catherine Anne Pickering
Employment - iOnctura
Leadership - iOnctura
Stock and Other Ownership Interests - iOnctura
 
Marco Durini
Employment - LabCorp
Leadership - LabCorp
Stock and Other Ownership Interests - LabCorp
Honoraria - LabCorp
Consulting or Advisory Role - LabCorp
Speakers' Bureau - LabCorp
Research Funding - LabCorp
Travel, Accommodations, Expenses - LabCorp
 
Ziyang Tan
No Relationships to Disclose
 
Lakshmikanth Tadepally
Stock and Other Ownership Interests - Cytodelics
Consulting or Advisory Role - Health Advances
 
Petter Brodin
No Relationships to Disclose
 
Mariaelena Occhipinti
Employment - Radiomics
Leadership - Radiomics
Stock and Other Ownership Interests - Radiomics
Consulting or Advisory Role - Radiomics
 
Matteo Simonelli
No Relationships to Disclose
 
Carmelo Carlo-Stella
Honoraria - AstraZeneca; Bristol-Myers Squibb; Celgene/Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Incyte; Janssen Oncology; Merck Sharp & Dohme; Novartis
Consulting or Advisory Role - ADC Therapeutics; Celgene/Bristol-Myers Squibb; Karyopharm Therapeutics; Novartis; Roche; Sanofi
Research Funding - ADC Therapeutics (Inst); Roche (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - ADC Therapeutics; Janssen; Roche; Takeda
 
Armando Santoro
Consulting or Advisory Role - ARQULE; Bayer; Bristol-Myers Squibb; Eisai; Gilead Sciences; Incyte; MSD; Pfizer; Sanofi; SERVIER
Speakers' Bureau - Abbvie; Amgen; ArQule; AstraZeneca; Bayer; BMS; Celgene; Eisai; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Roche; Sandoz; Servier; Takeda
 
Pavlina Spiliopoulou
No Relationships to Disclose
 
T.R. Jeffry Evans
Honoraria - Ascelia (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); Bristol Myers Squibb (Inst); Eisai (Inst); Medivir (Inst); Merck Sharp & Dohme (Inst); Nucana (Inst); Roche/Genentech (Inst)
Consulting or Advisory Role - Karus Therapeutics (Inst)
Speakers' Bureau - AstraZeneca (Inst); Bristol Myers Squibb (Inst); Eisai (Inst); Medivir (Inst); Merck Sharp & Dohme (Inst); Nucana (Inst); Roche/Genentech (Inst); United Medical (Inst)
Research Funding - Adaptimmune (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Athenex (Inst); Basilea (Inst); Beigene (Inst); Berg Pharma (Inst); Bicycle Therapeutics (Inst); BiolineRx (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); CytomX Therapeutics (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); Immunocore (Inst); iOnctura (Inst); Iovance Biotherapeutics (Inst); Janssen (Inst); Johnson & Johnson (Inst); Lilly (Inst); Medivir (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); MiNA Therapeutics (Inst); Modulate Pharma (Inst); Novartis (Inst); Nucana (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Sierra Pharma (Inst); Starpharma (Inst); UCB (Inst); Verastem (Inst); Vertex (Inst)
Expert Testimony - Medivir (Inst)
Travel, Accommodations, Expenses - Bristol Myers Squibb; Eisai; Merck Sharp & Dohme; Nucana; Pierre Fabre
Other Relationship - Genmab (Inst)
 
Michele Maio
Stock and Other Ownership Interests - Epigen Therapeutics; Theravance
Honoraria - Alfasigma; Amgen; AstraZeneca; Bristol-Myers Squibb; Lilly; Merck; MSD; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - Alfasigma; AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Pierre Fabre; Roche
Patents, Royalties, Other Intellectual Property - DNA Hypomethylating agents for cancer therapy
Travel, Accommodations, Expenses - Alfasigma; Amgen; AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Pierre Fabre; Roche